Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanfacine for positive BPSD symptoms of dementia
jRCTs031220715Completed
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of guanfacine in Dementia, Alzheimer's disease (AD), frontotemporal dementia (FTD) and 1 more. Primary endpoint: Frequency and rate of adverse events. Started Mar 2023; status: completed.
02
Drugs
guanfacine
03
Conditions
DementiaAlzheimer's disease (AD)frontotemporal dementia (FTD)vascular dementia
Beyond the preview
Go deeper on jRCTs031220715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220715.